DepYmed
NY-based DepYmed Inc. develops novel therapeutics for cancer and rare diseases, focusing on PTP1B inhibitors and copper chelators.
- 11
- Private company
- Farmingdale, NY, USUnited States
NY-based DepYmed Inc. develops novel therapeutics for cancer and rare diseases, focusing on PTP1B inhibitors and copper chelators.
depymed.comCrawled Oct 21, 2026
Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body.
Rett syndrome is a progressive neurodevelopmental disorder primarily affecting females, with rare cases in males. Infants typically develop normally before symptoms appear.
Disruption of Protein Tyrosine Phosphatase (PTP) function underlies cancer, inflammatory diseases, diabetes, neurological diseases including Alzheimer’s, and various rare diseases.
DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome By DepYmed, Inc. | March 19, 2024
DepYmed received FDA designations for Rare Pediatric Disease and Orphan Drug for its lead candidate treating Rett syndrome.
DepYmed’s compound DPM-1001 may offer a potential treatment for Wilson’s Disease, as reported by researchers at Cold Spring Harbor.
New employment opportunities will be posted as the corporation continues to grow. Please check back soon.
Leo Guthart founded Topspin in 2000 after serving as Vice Chairman of Pittway Corporation and CEO of its Security Group, including Ademco.
Nick Tonks earned a BA in Biochemistry from Oxford University and a PhD in Biochemistry from the University of Dundee, where he worked with Prof. Sir Philip Cohen.
Dr. Peter Van Ess has over 30 years of experience in scientific research and management, including 20 years in the global pharmaceutical industry.
Dr. Hariharan serves as Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, overseeing Research & Development, Regulatory Affairs, and Specialty divisions.
DepYmed is developing potent inhibitors of the enzyme PTP1B which can be applied as potential therapeutic agents for multiple diseases including Rett Syndrome, Wilson Disease and cancer.
DepYmed is developing potent inhibitors of the enzyme PTP1B which can be applied as potential therapeutic agents for multiple diseases including Rett Syndrome, Wilson Disease and cancer.